CSPC Pharmaceutical Group (1093.HK) announced that its subsidiary, CSPC Innovation Pharmaceutical Co., Ltd. (300765.SZ), recorded RMB1,593 million in operating revenue for the first nine months ended 30 September 2025, reflecting a 7.71% year-on-year increase. During the same period, net profit attributable to shareholders stood at -RMB24.05 million, representing a year-on-year shift of -117.26%. After excluding non-recurring items, net profit attributable to shareholders reached -RMB64.82 million, marking a year-on-year change of -147.40%.

According to unaudited figures prepared under the China Accounting Standards for Business Enterprises, CSPC Innovation saw a notable rise in trade receivables and trade payables, partly due to higher business volume and ongoing research and development initiatives. Selling expenses expanded by 87.12% year-on-year, while research and development expenses increased by 49.56%, influenced by intensified biopharmaceutical R&D activities. Other gains rose substantially, largely attributed to government grants received during the reporting period.

Net cash outflow from operating activities narrowed significantly year-on-year, primarily due to the settlement of previous research and development costs in the prior period, while net cash flow from financing activities turned positive. All data pertain exclusively to CSPC Innovation's performance and may differ from CSPC Pharmaceutical Group’s overall financials.